AKT inhibitor / Amgen - LARVOL DELTA

THE ABSOLUTE BIOAVAILABILITY AND ABSORPTION, METABOLISM, AND EXCRETION OF IPATASERTIB, A POTENT AND HIGHLY SELECTIVE AKT INHIBITOR. (PubMed, Drug Metab Dispos) - "Significance Statement The study provided definitive information regarding the absolute bioavailability and the absorption, metabolism, and excretion pathways of ipatasertib, a potent, novel, and highly selective small molecule Akt inhibitor. An ultrasensitive radioactive counting method, accelerator mass spectrometry (AMS) was successfully applied for C-microtracer absolute bioavailability determination and plasma metabolite profiling."

Journal • Oncology

[VIRTUAL] Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas (ASH 2020) - "Lenalidomide (LEN) is currently approved for use in indolent non-Hodgkin lymphomas, and has several potential synergistic and overlapping targets with PI3K/mTOR/Akt inhibition...The ORR for HL patients in the other lymphoma cohort, the majority of whom had relapsed after brentuximab vedotin (BV) and autologous stem cell transplantation (ASCT), was 80% (35% CR)...TEM and LEN may be a suitable option for treatment of HL after BV and ASCT, including as a bridge to allogeneic stem cell transplantation. Further study of PI3K/Akt/mTOR inhibition in combination with lenalidomide is warranted, particularly in relapsed HL."

Clinical • P1/2 data • Cardiovascular • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Infectious Disease • Lymphoma • Mucositis • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Septic Shock • Transplantation